Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|October 3, 2014
Product Suitability for Intended End Use
This podcast will review BioSpectra?s interpretation of product suitability for intended end use. We will go over the meaning of product suitability as well as provide types of end use applications supported by BioSpectra?s products. Additionally, we will provide examples of BioSpectra?s offerings and key differences of these offerings based on intended end use.
This podcast will review BioSpectra’s interpretation of product suitability for intended end use. We will go over the meaning of product suitability as well as provide types of end use applications supported by BioSpectra’s products. Additionally, we will provide examples of BioSpectra’s offerings and key differences of these offerings based on intended end use.
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.